Artificial Intelligence (AI) is rapidly transforming regulated industries, including pharmaceuticals, medical devices, and biologics. From predictive analytics and batch record review to deviation trending and inspection readiness, AI offers unprecedented efficiency. However, one fundamental reality remains: AI systems are not error-free—and may never be.
Unlike traditional software, AI systems—especially machine learning and generative AI—operate probabilistically. This means outputs can vary, contain bias, hallucinate information, or produce inconsistent results. In highly regulated environments governed by agencies such as the U.S. Food and Drug Administration, even small inaccuracies can have major compliance and patient safety implications.
This session explores the regulatory, ethical, and operational implications of AI’s inherent error potential. Participants will gain clarity on validation expectations, risk management strategies, and how to responsibly integrate AI within FDA-regulated systems while maintaining GMP compliance and data integrity.
Rather than asking whether AI can be perfect, this course reframes the question: How do we build controls, oversight, and governance models that make AI safe, compliant, and inspection-ready?
Learning Objectives:-
By the end of this session, participants will be able to:
Session Highlights:-
Attendees will leave with a practical framework for deploying AI responsibly in regulated environments without compromising compliance or patient safety.
Areas Covered During the Session:-
Background:-
As AI tools increasingly support documentation review, predictive maintenance, deviation investigations, and even regulatory submissions, organizations face a new compliance frontier. Unlike traditional automation systems, AI models evolve, retrain, and may produce non-repeatable outputs. This challenges long-standing regulatory paradigms built on consistency and reproducibility.
The FDA has signaled growing interest in AI governance, transparency, and lifecycle oversight. Organizations must shift from a “validate once” mindset to a continuous monitoring and control strategy. This topic builds awareness of AI’s structural limitations and provides a defensible framework for compliant integration into regulated operations.
Why Should You Attend?
AI adoption is accelerating—but regulatory expectations remain stringent. Understanding how AI errors intersect with GMP requirements, validation standards, and FDA scrutiny is essential before implementation.
Who Will Benefit?
Professionals working in FDA-regulated and GMP environments, including:
Ginette Collazo, Ph. D. is an Industrial-Organizational Psychologist with 20 years of experience that specializes in Engineering Psychology and Human Reliability, disciplines that study the interaction between human behavior and productivity. She has held positions leading training and human reliability programs in the Pharmaceutical and Medical Device Manufacturing Industry.
Nine years ago, Dr. Collazo established Human Error Solutions (HES), a Florida-based boutique consulting firm, where she has been able to position herself as one of the few Human Error Reduction Experts in the world. HES, led by Dr. Collazo, developed a unique methodology for human error investigations, cause determination, CA-PA development, and effectiveness that has been implemented and proven amongst different industries globally. This scientific method has been applied in critical quality situations and workplace accidents.
She is the author of the book Human Error: Root Cause Determination Model, published in 2008. She is also a speaker at significant events like Interphex, FDAnews Annual Conference, Global Conference on Process Safety, International Conference on Applied Human Factors and Ergonomics, and of course, Pharmaceutical Industry Association.